Drug Profile
Research programme: fetal growth retardation gene therapy - Magnus Life Science
Alternative Names: Fetal growth retardation gene therapy - Magnus GrowthLatest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator Magnus Life Science; University College London
- Class Gene therapies
- Mechanism of Action Vascular endothelial growth factor A expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Fetal growth retardation
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Fetal growth retardation in United Kingdom (Intra-arterial)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Fetal-growth-retardation in United Kingdom (Intra-arterial, Injection)
- 08 Jan 2015 European Medicines Agency (EMA)'s Committee for Orphan Medicinal Products (COMP) recommends orphan drug designation for gene therapy in European Union for Fetal growth retardation